CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The Burden of Cardiovascular Diseases Among US States, 1990-2016 Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Minimizing Permanent Pacemaker Following Repositionable Self-Expanding Transcatheter Aortic Valve Replacement Sleep quality and risk of coronary heart disease-a prospective cohort study from the English longitudinal study of ageing Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Regional Heterogeneity in the Coronary Vascular Response in Women With Chest Pain and Nonobstructive Coronary Artery Disease The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older Sequence variations in PCSK9, low LDL, and protection against coronary heart disease Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

Clinical Trial2017 Dec 20. [Epub ahead of print]

JOURNAL:J Interv Cardiol. Article Link

Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions

Ito R, Ueno K, Yoshida T et al. Keywords: calcified coronary lesions; drug-coated balloon

ABSTRACT


OBJECTIVES - To investigate the efficacy of drug-coated balloon (DCB) for calcified coronary lesions.


BACKGROUND - Calcified coronary lesions is associated with poor clinical outcomes after revascularization. Recently, DCB is emerging as an alternative strategy for de novo coronary lesions. However, reports describing the efficacy of DCB for calcified coronary lesions are limited.


METHODS - A total of 81 patients (96 lesions) who electively underwent DCB treatment for de novo coronarylesions were enrolled: 46 patients (55 lesions) in the calcified group and 35 patients (41 lesions) in the non-calcified group. Angiographic follow-up data and clinical outcomes after the procedure were evaluated.


RESULTS - The diameter of the DCB used was 2.5 ± 0.5 mm. No bail-out stenting was observed after DCB treatment. Rotational atherectomy was used in 82% of lesions in the calcified group. Follow-up angiography (median, 6.5 months after intervention) was performed for 59 patients (30 in the calcified group and 29 in the non-calcified group). Late lumen loss and rates of restenosis were comparable between the groups (0.03 mm in the calcified group vs -0.18 mm in the non-calcified group, P = 0.093 and 13.9% vs 3.03%, P = 0.095, respectively). The survival rates for target lesion revascularization free survival and major adverse cardiac events at 2 years were comparable between the groups (85.3% vs 93.4%, P = 0.64 and 81.4% vs 88.5%, P = 0.57, respectively).


CONCLUSION - Calcified coronary lesions might dilute the effect of DCB. However, clinical outcomes in the calcified group were similar to those in the non-calcified group.


© 2017, Wiley Periodicals, Inc.